ASCO 2023 | The role of molecular subtyping in DLBCL and implications for treatment decisions
In this video, Manali Kamdar, MD, University of Colorado, Aurora, CO, shares some insights into the importance of further investigating the heterogeneity of diffuse large B-cell lymphoma (DLBCL) and how this may guide treatment decisions and clinical trial design. Dr Kamdar first highlights the two major subtypes of DLBCL, germinal center B-cell (GCB) and activated B-cell (ABC), and further comments on the outcomes associated with these. To conclude, Dr Kamdar discusses advances made in the understanding of DLBCL disease biology with the POLARIX trial (NCT03274492), and further highlights strategies to improve outcomes for various subtypes of DLBCL in the future. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
